A 12 Week, Randomized, Open-Label, Parallel Group Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX (160/4.5 and 320/9 mcg) as Compared to SYMBICORT TURBOHALER (200/6 and 400/12 mcg) as Treatment for Adult Patients With Asthma

Trial Profile

A 12 Week, Randomized, Open-Label, Parallel Group Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX (160/4.5 and 320/9 mcg) as Compared to SYMBICORT TURBOHALER (200/6 and 400/12 mcg) as Treatment for Adult Patients With Asthma

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Dec 2015

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms ELIOT
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 09 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Jan 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 14 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Apr 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top